Loading...
•
Mar 31, 2025
Vir Q1 2025 Earnings Report
Vir Biotechnology reported its financial results for the first quarter ended March 31, 2025, highlighting significant progress in its clinical programs and a strong financial position.
Key Takeaways
Vir Biotechnology reported a net loss of $120.965 million for Q1 2025, compared to a net loss of $65.276 million in Q1 2024. Total revenues decreased significantly to $3.032 million from $56.376 million in the prior year, primarily due to the expiration of GSK's rights. The company maintains a strong financial position with approximately $1.02 billion in cash and investments, providing a runway into mid-2027.
Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with the first patient enrolled in Q1 2025, with the program receiving U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations.
Continued dose escalation for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA), with promising early Phase 1 safety profiles and no dose-limiting cytokine release syndrome observed.
On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025.
Reported a significant decrease in total revenues to $3.032 million in Q1 2025 from $56.376 million in Q1 2024, primarily due to the expiration of GSK's rights to select additional non-influenza target pathogens.
Revenue by Segment
Forward Guidance
Based on current operating plans, Vir Biotechnology expects its cash, cash equivalents, and investments to fund its operations into mid-2027.
Positive Outlook
- Initiation of Phase 3 registrational ECLIPSE program for chronic hepatitis delta.
- Continued dose escalation and promising early Phase 1 data for VIR-5818 and VIR-5500.
- Planned initiation of a Phase 1 study for VIR-5525 in Q2 2025.
- Strong financial position with approximately $1.0 billion in cash and investments.
- Advancement of a broadly neutralizing antibody to development candidate status in HIV cure program.
Challenges Ahead
- Future advancement in Chronic Hepatitis B (CHB) is contingent on securing a worldwide development and commercialization partner.
- Significant decrease in total revenues compared to the prior year due to the expiration of GSK's rights.
- Net loss increased to $120.965 million in Q1 2025 from $65.276 million in Q1 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...